Treatment of hypogonadotropic male hypogonadism: Case-based scenarios

doi:10.5527/wjn.v4.i2.245

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14456)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

752

WORD

417

HTML

10309

Figures (1-1)

305

Tables (1-1)

233

Sum=12016

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

993

Download

1447

Sum=2440

May 6, 2015 (publication date) through Dec 12, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Nephrol. May 6, 2015; 4(2): 245-253
Published online May 6, 2015. doi: 10.5527/wjn.v4.i2.245

Full Size Figure Download Figure

Figure 1 Hypogonadism therapeutic hormones and mechanism of action. Exogenous T and anabolic steroids negatively affect the HPG axis. SERMs such as CC stop the negative feedback of estrogen on the HPG axis. hCG stimulates Leydig cells. Aromatase inhibitors inhibit the conversion of T to E. LH: Luteinizing hormone; FSH: Follicle-stimulating hormone; AAS: Anabolic-Androgenic steroid; hCG: Human chorionic gonadotropin; GnRH: Gonadotropin-releasing hormone.

Citation: Crosnoe-Shipley LE, Elkelany OO, Rahnema CD, Kim ED. Treatment of hypogonadotropic male hypogonadism: Case-based scenarios. World J Nephrol 2015; 4(2): 245-253
URL: https://www.wjgnet.com/2220-6124/full/v4/i2/245.htm
DOI: https://dx.doi.org/10.5527/wjn.v4.i2.245